

NA Travel Vaccine Market - Industry Trends and Forecast to 2035

Market Report | 2024-03-01 | 238 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America travel vaccine market is expected to reach USD 3,999,023.57 thousand by 2032 from USD 1,743,097.85 thousand in 2023, growing at a substantial CAGR of 9.8% in the forecast period of 2024 to 2032.

Market Segmentation:

By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric and Geriatric), Age Group (20-50 Years, Less than 20 Years and Above 50 Years), Distribution Channel (B2B and B2C), Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2032

Some of the major factors contributing to the growth of the North America travel vaccines market are:

Driver

- Rising incidence of infectious diseases

Restraint

- High cost of travel vaccines

Opportunity

- Advancements in vaccine technology

Market Players

Some major companies dealing in the North America travel vaccines market are:

- GSK plc.
- Bavarian Nordic
- Pfizer Inc.
- Abbott

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- CSL
- AstraZeneca
- Sanofi
- Merck & Co., Inc.
- Valneva SE
- Johnson & Johnson Services Inc.
- Dynavax Technologies.

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	49
1.1 OBJECTIVES OF THE STUDY	49
1.2 MARKET DEFINITION	49
1.3 OVERVIEW OF NORTH AMERICA TRAVEL VACCINES MARKET	49
1.4 LIMITATIONS	51
1.5 MARKETS COVERED	51
2 MARKET SEGMENTATION	55
2.1 MARKETS COVERED	55
2.2 GEOGRAPHICAL SCOPE	56
2.3 YEARS CONSIDERED FOR THE STUDY	57
2.4 CURRENCY AND PRICING	57
2.5 DBMR TRIPOD DATA VALIDATION MODEL	58
2.6 MULTIVARIATE MODELLING	61
2.7 PRODUCT TYPE LIFELINE CURVE	61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	62
2.9 DBMR MARKET POSITION GRID	63
2.10 MARKET APPLICATION COVERAGE GRID	64
2.11 VENDOR SHARE ANALYSIS	65
2.12 SECONDARY SOURCES	66
2.13 ASSUMPTIONS	66
3 EXECUTIVE SUMMARY	67
4 PREMIUM INSIGHTS	70
4.1 PESTEL ANALYSIS	71
4.2 PORTER'S FIVE FORCES	72
4.3 PIPELINE ANALYSIS	73
5 MARKET OVERVIEW	77
5.1 DRIVERS	79
5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES	79
5.1.2 INCREASING TRAVEL AND TOURISM	81
5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION	82
5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS	82
5.2 RESTRAINTS	83
5.2.1 HIGH COST OF TRAVEL VACCINES	83
5.2.2 REGULATORY HURDLES FOR APPROVAL	84
?	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3 OPPORTUNITIES	84
5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY	84
5.3.2 GROWING AWARENESS REGARDING VACCINES	85
5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS	85
5.4 CHALLENGES	86
5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE	86
5.4.2 VACCINE HESITANCY AND MISINFORMATION	87
6 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION	88
6.1 OVERVIEW	89
6.2 COMBINATION VACCINES	92
6.3 MONO VACCINES	92
7 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE	93
7.1 OVERVIEW	94
7.2 INACTIVATED VACCINES	97
7.2.1 HEPATITIS A	98
7.2.2 INFLUENZA	98
7.2.3 RABIES	98
7.2.4 TICK-BORNE ENCEPHALITIS	98
7.2.5 JAPANESE ENCEPHALITIS	98
7.2.6 POLIO	99
7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES	99
7.3.1 HEPATITIS B	100
7.3.2 MENINGOCOCCAL	100
7.3.3 MALARIA	100
7.3.4 COVID-19	100
7.4 LIVE-ATTENUATED VACCINES	101
7.4.1 TYPHOID	102
7.4.2 CHOLERA	102
7.4.3 YELLOW FEVER	102
7.4.4 MEASLES	102
7.4.5 MUMPS	103
7.4.6 RUBELLA	103
7.4.7 VARICELLA	103
7.4.8 OTHERS	103
7.5 TOXOID VACCINES	103
7.5.1 DIPHTHERIA	104
7.5.2 TETANUS	104
7.6 DNA VACCINES	104
7.7 VIRAL VECTOR VACCINES	105
8 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY	106
8.1 OVERVIEW	107
8.2 RECOMMENDED VACCINE	110
8.2.1 TYPHOID FEVER VACCINES	111
8.2.2 HEPATITIS A	111
8.2.3 CHOLERA	111
8.2.4 RABIES	111
8.2.5 TICK-BORNE ENCEPHALITIS	111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.6 JAPANESE ENCEPHALITIS	111
8.2.7 MALARIA	111
8.2.8 OTHERS	111
8.3 ROUTINE VACCINE	112
8.3.1 HEPATITIS B	113
8.3.2 INFLUENZA VACCINES	113
8.3.3 PNEUMOCOCCAL	113
8.3.4 DIPHTHERIA	113
8.3.5 TETANUS	113
8.3.6 MEASLES	113
8.3.7 MUMPS	113
8.3.8 RUBELLA	113
8.3.9 PERTUSSIS	113
8.3.10 OTHERS	114
8.4 REQUIRED VACCINE	114
8.4.1 YELLOW FEVER	115
8.4.2 MENINGOCOCCAL	115
8.4.3 POLIO VACCINES	115
9 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE	116
9.1 OVERVIEW	117
9.2 TYPHOID	121
9.3 HEPATITIS	121
9.3.1 HEPATITIS A	122
9.3.2 HEPATITIS B	122
9.4 CHOLERA	122
9.5 VARICELLA	123
9.6 INFLUENZA	123
9.7 JAPANESE ENCEPHALITIS	124
9.8 MENINGOCOCCAL MENINGITIS	124
9.9 YELLOW FEVER	125
9.10 RABIES	125
9.11 DPT	126
9.12 MEASLES AND MUMPS	126
9.13 TICK-BORNE ENCEPHALITIS	127
9.14 MALARIA	127
9.15 COVID-19	128
9.16 POLIO	128
9.17 OTHERS	129
10 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION	130
10.1 OVERVIEW	131
10.2 INJECTABLE	134
10.2.1 INTRAMUSCULAR	135
10.2.2 SUBCUTANEOUS	135
10.2.3 OTHERS	135
10.3 ORAL	135
11 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER	136
11.1 OVERVIEW	137

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.2 MALE	140
11.3 FEMALE	140
12 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE	141
12.1 OVERVIEW	142
12.2 ADULT	145
12.3 PEDIATRIC	145
12.4 GERIATRIC	146
13 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP	147
13.1 OVERVIEW	148
13.2 20-50 YEARS	151
13.3 LESS THAN 20 YEARS	152
13.4 ABOVE 50 YEARS	153
14 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL	154
14.1 OVERVIEW	155
14.2 B2B	158
14.3 B2C	158
?	
15 NORTH AMERICA TRAVEL VACCINE MARKET, BY REGION	159
15.1 NORTH AMERICA	162
15.1.1 U.S.	170
15.1.2 CANADA	177
15.1.3 MEXICO	185
16 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY LANDSCAPE	192
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	192
17 SWOT ANALYSIS	193
18 COMPANY PROFILE	194
18.1 PFIZER INC.	194
18.1.1 COMPANY SNAPSHOT	194
18.1.2 REVENUE ANALYSIS	194
18.1.3 COMPANY SHARE ANALYSIS	195
18.1.4 PRODUCT PORTFOLIO	195
18.1.5 RECENT DEVELOPMENT	196
18.2 SANOFI	197
18.2.1 COMPANY SNAPSHOT	197
18.2.2 REVENUE ANALYSIS	197
18.2.3 COMPANY SHARE ANALYSIS	198
18.2.4 PRODUCT PORTFOLIO	198
18.2.5 RECENT DEVELOPMENT	202
18.3 JOHNSON & JOHNSON SERVICES INC.	203
18.3.1 COMPANY SNAPSHOT	203
18.3.2 REVENUE ANALYSIS	203
18.3.3 COMPANY SHARE ANALYSIS	204
18.3.4 PRODUCT PORTFOLIO	204
18.3.5 RECENT DEVELOPMENTS	205
18.4 GSK PLC.	206
18.4.1 COMPANY SNAPSHOT	206
18.4.2 REVENUE ANALYSIS	206

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.4.3 COMPANY SHARE ANALYSIS	207
18.4.4 PRODUCT PORTFOLIO	207
18.4.5 RECENT DEVELOPMENT	212
18.5 MERCK & CO., INC.	214
18.5.1 COMPANY SNAPSHOT	214
18.5.2 REVENUE ANALYSIS	214
18.5.3 COMPANY SHARE ANALYSIS	215
18.5.4 PRODUCT PORTFOLIO	215
18.5.5 RECENT DEVELOPMENT	217
18.6 ABBOTT	218
18.6.1 COMPANY SNAPSHOT	218
18.6.2 REVENUE ANALYSIS	218
18.6.3 PRODUCT PORTFOLIO	219
18.6.4 RECENT DEVELOPMENT	220
18.7 ASTRAZENECA	221
18.7.1 COMPANY SNAPSHOT	221
18.7.2 REVENUE ANALYSIS	221
18.7.3 PRODUCT PORTFOLIO	222
18.7.4 RECENT DEVELOPMENT	222
18.8 BAVARIAN NORDIC	224
18.8.1 COMPANY SNAPSHOT	224
18.8.2 REVENUE ANALYSIS	224
18.8.3 PRODUCT PORTFOLIO	225
18.8.4 RECENT DEVELOPMENT	225
18.9 CSL	227
18.9.1 COMPANY SNAPSHOT	227
18.9.2 REVENUE ANALYSIS	227
18.9.3 PRODUCT PORTFOLIO	228
18.9.4 RECENT DEVELOPMENT	229
18.10 DYNAVAX TECHNOLOGIES.	230
18.10.1 COMPANY SNAPSHOT	230
18.10.2 REVENUE ANALYSIS	230
18.10.3 PRODUCT PORTFOLIO	231
18.10.4 RECENT DEVELOPMENTS	231
18.11 VALNEVA SE	232
18.11.1 COMPANY SNAPSHOT	232
18.11.2 REVENUE ANALYSIS	232
18.11.3 PRODUCT PORTFOLIO	233
18.11.4 RECENT DEVELOPMENT	233
19 QUESTIONNAIRE	234
20 RELATED REPORTS	238

NA Travel Vaccine Market - Industry Trends and Forecast to 2035

Market Report | 2024-03-01 | 238 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com